Oncopeptides AB(DE:OND)
€0.16+0.01 (+10.07%)
DE:OND
Oncopeptides AB ownership
€0.16
At close:+0.01 (+10.07%)
Oncopeptides AB (OND) Ownership - Who Owns Oncopeptides AB?
6 Followers
Oncopeptides AB (OND) Ownership Overview
- 0.68% Insiders
- 99.32% Public Companies and Individual Investors
The ownership structure of Oncopeptides AB (DE:OND) stock is a mix of institutional, retail, and individual investors. , 0.68% is owned by Insiders, and 99.32% is owned by Public Companies and Individual Investors.
The ownership structure of Oncopeptides AB (DE:OND) stock is a mix of institutional, retail, and individual investors. , 0.68% is owned by Insiders, and 99.32% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Mar 17, 2026 | Christine Elizabeth Rankin | kr 23,775 | |
| Mar 16, 2026 | David Augustsson | kr 22,000 | |
| Mar 16, 2026 | Henrik Bergentoft | kr 22,100 | |
| Mar 16, 2026 | Sofia Heigis | kr 136,141 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Per Wold-olsen | 2,065,678 | Insider | 0.48% | 373,888 |
| Eva Sabina Marianne Nordström | 420,696 | Insider | 0.10% | 76,146 |
| Sofia Heigis | 263,499 | Insider | 0.06% | 47,693 |
| Christine Elizabeth Rankin | 103,790 | Insider | 0.02% | 18,786 |
| Henrik Bergentoft | 42,774 | Insider | <0.01% | 7,742 |
| David Augustsson | 41,583 | Insider | <0.01% | 7,527 |
FAQ
What percentage of Oncopeptides AB (DE:OND) stock is held by retail investors?
According to the latest TipRanks data, approximately 99.32% of Oncopeptides AB (DE:OND) stock is held by public companies and individual investors.
Who owns the most shares of Oncopeptides AB (DE:OND)?
Per Wold-Olsen owns the most shares of Oncopeptides AB (DE:OND).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
